Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.32 USD
-0.24 (-4.32%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.42 +0.10 (1.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
EDIT 5.32 -0.24(-4.32%)
Will EDIT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Other News for EDIT
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal Prudence
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas announces preclinical data from in vivo gene editing medicines
Editas Medicine upgraded at J.P. Morgan on recent weakness